The road not taken: Transferability issues in multinational trials

PharmacoEconomics

Volumn 31, Issue 10, 2013, Pages 863-876

  Vemer, Pepijn ^a   Rutten Van Mölken, Maureen P M H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANESTHETIC AGENT; ATORVASTATIN; AZATHIOPRINE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CALCIPOTRIOL; CAPTOPRIL; CLOPIDOGREL; ENOXAPARIN; EPLERENONE; EVEROLIMUS; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GRASS POLLEN VACCINE; HEPARIN; LEVOCETIRIZINE; LISINOPRIL; PLACEBO; PRAVASTATIN; RIVASTIGMINE; ROFLUMILAST; ROSUVASTATIN; SALMETEROL; TACALCITOL; VALSARTAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ALLERGIC RHINOCONJUNCTIVITIS; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; ECONOMIC EVALUATION; HEALTH; HEALTH CARE UTILIZATION; HEART FAILURE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MEASUREMENT; MULTINATIONAL RANDOMIZED CONTROLLED TRIAL; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINITIS; RHINOCONJUNCTIVITIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW;

COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; DECISION MAKING; HEALTH SERVICES; HUMANS; INTERNATIONAL COOPERATION; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACEUTICAL PREPARATIONS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REIMBURSEMENT MECHANISMS;

EID: 84886015840     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0084-z     Document Type: Review

References (57)

1. Willan AR, Pinto EM, O'Brien BJ, Kaul P, Goeree R, Lynd L, et al. Country-specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. Health Econ. 2005;14(4):327-38.
2. Barbieri MA, Drummond MF, Willke R, Chancellor JVM, Jolain B, Towse A. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health. 2005;8(1):10-23.
3. Rutten-van Mölken MPMH, Vemer P. Internationale vertaalbaarheid van kosten-effectiviteit [International transferability of cost-effectiveness]. Van Kosten tot Effecten Een handleiding voor evaluatiestudies in de gezondheidszorg [From Costs to Effects. A manual for evaluation studies in health care]. 2nd ed. Maarssen: ELSEVIER gezondheidszorg; 2010. p. 270.
4. Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ. 1998;7(6):481-93.
5. Koopmanschap MA, Touw KC, Rutten FFH. Analysis of costs and cost-effectiveness in multinational trials. Health Policy. 2001;58(2):175-86.
6. Clarke PM, Glasziou P, Patel A, Chalmers J, Woodward M, Harrap SB, et al. Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Med. 2010;7(2):e1000236.
7. Goldstein H. Multilevel statistical models. 2nd ed. London: Edward Arnold; 1995.
8. Rice N, Jones A. Multilevel models and health economics. Health Econ. 1997;6(6):561-75.
9. Carey K. A multilevel modelling approach to analysis of patient costs under managed care. Health Econ. 2000;9(5):435-46.
10. Nixon RM, Thompson SG. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. Health Econ. 2005;14(12):1217-29.
11. Grieve R, Nixon R, Thompson SG, Normand C. Using multilevel models for assessing the variability of multinational resource use and cost data. Health Econ. 2005;14(2):185-96.
12. Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Econ. 2005;14(5):471-85.
13. Pinto EM, Willan AR, O'Brien BJ. Cost-effectiveness analysis for multinational clinical trials. Stat Med. 2005;24(13):1965-82.
14. Gauthier A, Manca A, Anton S. Bayesian modelling of healthcare resource use in multinational randomized clinical trials. Pharmacoeconomics. 2009;27(12):1017-29.
15. Manca A, Sculpher MJ, Goeree R. The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments. Pharmacoeconomics. 2010;28(12):1079-96.
16. Drummond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12(4):409-18.
17. Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlof B, Sever PS, et al. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Eur J Cardiovasc Prev Rehabil. 2005;12(1):29-36.
18. Löfdahl CG, Ericsson A, Svensson K, Andreasson E. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics. 2005;23(4):365-75.
19. Peeters P, Ortonne JP, Sitbon R, Guignard E. Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of Psoriasis vulgaris. Dermatology. 2005;211(2):139-45.
20. Radeva JI, Reed SD, Kalo Z, Kauf TL, Cantu E 3rd, Cretin N, et al. Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation. Clin Transpl. 2005;19(1):122-9.
21. Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, et al. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). Am Heart J. 2005;150(2):323-9.
22. Weintraub WS, Mahoney EM, Lamy A, Culler S, Yuan Y, Caro J, et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol. 2005;45(6):838-45.
23. Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation. 2005;111(9):1106-13.
24. Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJ, Pedersen SE, et al. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy. 2006;61(5):531-6.
25. Tonkin AM, Eckermann S, White H, Friedlander D, Glasziou P, Magnus P, et al. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study. Am Heart J. 2006;151(6):1305-12.
26. Willan AR, Goeree R, Pullenayegum EM, McBurney C, Blackhouse G. Economic evaluation of rivastigmine in patients with Parkinson's disease dementia. Pharmacoeconomics. 2006;24(1):93-106.
27. Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis: a Northern European perspective. Clin Exp Allergy. 2007;37(5):772-9.
28. Canonica GW, Poulsen PB, Vestenbaek U. Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. Respir Med. 2007;101(9):1885-94.
29. Manca A, Lambert PC, Sculpher M, Rice N. Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling. Med Decis Mak. 2007;27(4):471-90.
30. Rutten-van Mölken MPMH, van Nooten FE, Lindemann M, Caeser M, Calverley PM. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics. 2007;25(8):695-711.
31. Willan AR, Kowgier ME. Cost-effectiveness analysis of a multinational RCT with a binary measure of effectiveness and an interacting covariate. Health Econ. 2008;17(7):777-91.
32. Marcoff L, Zhang Z, Zhang W, Ewen E, Jurkovitz C, Leguet P, et al. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study. J Am Coll Cardiol. 2009;54(14):1271-9.
33. Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PM, Jones PW, et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J. 2010;35(3):532-9.
34. Gomes M, Soares MO, Dumville JC, Lewis SC, Torgerson DJ, Bodenham AR, et al. Cost-effectiveness analysis of general anaesthesia versus local anaesthesia for carotid surgery (GALA Trial). Br J Surg. 2010;97(8):1218-25.
35. Lorgelly PK, Briggs AH, Wedel H, Dunselman P, Hjalmarson A, Kjekshus J, et al. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. Eur J Heart Fail. 2010;12(1):66-74.
36. Rogkakou A, Villa E, Garelli V, Canonica GW. Persistent allergic rhinitis and the XPERT study. World Allergy Organ J. 2011;4(Suppl. 3):S32-6.
37. Dolan P. Modeling valuations for the EuroQol health states. Med Care. 1997;35:1095-108.
38. Drummond M, Sulpher M, Torrance G, O'Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
39. Briggs A, Scuplher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
40. Cook JR, Drummond MF, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Stat Med. 2003;22(12):1955-76.
41. O'Hagan A, Stevens JW, Montmartin J. Bayesian cost-effectiveness analysis from clinical trial data. Stat Med. 2001;20(5):733-53.
42. Drummond MF, Bloom BS, Carrin G, Hillman AL, Hutchings AC, Knill-Jones RP, et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care. 1992;8(4):671-82.
43. Drummond MF, Pang F. Transferability of economic evaluation results. In: Drummond MF, McGuire A, editors. Economic evaluation in health care; merging theory with practice. 1st ed. Oxford: Oxford University Press; 2001.
44. Pang F. Design, analysis and presentation of multinational economic studies: the need for guidance. Pharmacoeconomics. 2002;20(2):75-90.
45. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian data analysis. New York: Chapman & Hall/CRC; 2004.
46. Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, Cohen DJ, et al. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J. 2005;149(3):434-43.
47. ISPOR. Pharmacoeconomic guidelines from around the world. 2013. http://www.ispor.org/PEguidelines/index.asp. Accessed March 2013.
48. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2006.
49. Badia X, Roset M, Herdman M, Kind P. A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Mak. 2001;21(1):7-16.
50. Greiner W, Claes C, Busschbach J, Graf von der Schulenburg J. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ. 2004. [Epub ahead of print].
51. Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ. 2006;15(10):1121-32.
52. Knies S, Evers SM, Candel MJ, Severens JL, Ament AJ. Utilities of the EQ-5D: transferable or not? Pharmacoeconomics. 2009;27(9):767-79.
53. Glick H, Doshi J, Sonnad S, Polsky D. Economic evaluation in clinical trials. New York: Oxford University Press; 2007.
54. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics. 1985;41(2):361-72.
55. Piantadosi S, Gail MH. A comparison of the power of two tests for qualitative interactions. Stat Med. 1993;12(13):1239-48.
56. Pan G, Wolfe DA. Test for qualitative interaction of clinical significance. Stat Med. 1997;16(14):1645-52.
57. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics 2013;31(5):361-7. doi: 10.1007/s40273-013-0032-y.